Related Experiment Video
Updated: Dec 30, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Gut Bacterial Metabolite Urolithin A Decreases Actin Polymerization and Migration in Cancer Cells
Md Alauddin1, Toshiyuki Okumura1,2, Janet Rajaxavier1
1Department of Women's Health, Eberhard Karls University of Tuebingen, Tübingen, 72076, Germany.
Scope:
Urolithin A (UA) is a gut-derived bacterial metabolite from ellagic acid found in pomegranates, berries, and nuts can downregulate cell proliferation and migration. Cell proliferation and cell motility require actin reorganization, which is under control of ras-related C3 botulinum toxin substrate 1 (Rac1) and p21 protein-activated kinase 1 (PAK1). The present study explores whether UA can modify actin cytoskeleton in cancer cells.
Methods:
The effect of UA on globular over filamentous actin ratio is determined utilizing Western blotting, immunofluorescence, and flow cytometry. Rac1 and PAK1 levels are measured by quantitative RT-PCR and immunoblotting. As a result, a 24 h treatment with UA (20 µm) significantly decreased Rac1 and PAK1 transcript levels and activity, depolymerized actin and wound healing. The effect of UA on actin polymerization is mimicked by pharmacological inhibition of Rac1 and PAK1. The effect is also mirrored by knock down using siRNA.
Conclusion:
UA leads to disruption of Rac1 and Pak1 activity with subsequent actin depolymerization and migration. Thus, use of dietary UA in cancer prevention or as adjuvant therapy is promising.
Insights
Urolithin A (UA), a metabolite from ellagic acid, disrupts cancer cell migration by affecting actin cytoskeleton regulation via Rac1 and PAK1. This dietary compound shows promise for cancer prevention and therapy.
Area of Science:
- Cell Biology
- Molecular Biology
- Cancer Research
Background:
- Urolithin A (UA) is a gut-derived metabolite of ellagic acid found in fruits and nuts.
- Cell proliferation and migration are critical processes in cancer.
- Actin cytoskeleton dynamics, regulated by Rac1 and PAK1, are essential for cell motility.
Purpose of the Study:
- To investigate the effect of Urolithin A (UA) on the actin cytoskeleton in cancer cells.
- To determine if UA modulates the activity of Rac1 and PAK1 pathways.
- To explore the potential of UA in cancer prevention and therapy.
Main Methods:
- Quantitative RT-PCR and immunoblotting were used to measure Rac1 and PAK1 levels.
- Western blotting, immunofluorescence, and flow cytometry assessed the globular to filamentous actin ratio.
- Cancer cell migration was evaluated using wound healing assays.
Main Results:
- UA treatment (20 µm for 24 h) significantly reduced Rac1 and PAK1 transcript levels and activity.
- UA induced actin depolymerization, decreasing the G:F-actin ratio.
- UA treatment inhibited cancer cell migration, an effect mimicked by Rac1/PAK1 inhibition or knockdown.
Conclusions:
- Urolithin A disrupts Rac1 and PAK1 activity, leading to actin depolymerization and reduced cancer cell migration.
- Dietary Urolithin A demonstrates potential as a cancer preventive agent or adjuvant therapy.
- Targeting Rac1 and PAK1 pathways with UA offers a promising strategy in cancer treatment.
Related Concept Videos
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules
Actin Polymerization and Cell Motility
Actin cytoskeleton dynamics can produce pushing, pulling, and resistance forces that help the cell to migrate....
Urinary Tract Calculi III: Medical Management
Cancer Cell Migration through Invadopodia
Microtubule Formation

